Lupin has launched generic Pristiq (Desvenlafaxine Succinate) Extended-Release Tablets, 50 mg and 100 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin’s Desvenlafaxine Succinate Extended-Release Tablets, 50 mg and 100 mg, is the AB rated generic equivalent of Wyeth Pharmaceuticals’ Pristiq Tablets. It is indicated for the treatment of major depressive disorder (MDD). Pristiq tablets had annual US sales of around $859.9 million as per IMS MAT December 2016.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.